https://www.selleckchem.com/pr....oducts/Orlistat(Alli
Although other factors, as well as efficacy considerations will likely influence clinical decision making, genotype may be an important factor when determining dose. These findings add to a growing body of literature that suggest patients with UGT1A1 *28 or *6 variant alleles benefit from lower doses of irinotecan. However, due to the heterogeneity of currently available studies, more evidence that investigates various regimens in different patient populations is needed to determine the most appropriate dosing strategies. Althoug
Like
Comment
Share
